Anthony J. Guzzo - Jun 4, 2021 Form 3 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
VP, Chief Accounting Officer
Signature
/s/ Larry Miller, Attorney-in-Fact for Anthony J. Guzzo
Stock symbol
PHAT
Transactions as of
Jun 4, 2021
Transactions value $
$0
Form type
3
Date filed
6/11/2021, 04:44 PM
Next filing
Jan 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PHAT Common Stock 804 Jun 4, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PHAT Stock Option (Right to Buy) Jun 4, 2021 Common Stock 57.5K $25.06 Direct F2
holding PHAT Stock Option (Right to Buy) Jun 4, 2021 Common Stock 12K $32.20 Direct F3
holding PHAT Stock Option (Right to Buy) Jun 4, 2021 Common Stock 24.3K $39.11 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan on January 14, 2021.
F2 The option vested with respect to 25% of the shares of common stock on March 16, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.
F3 The option will vest with respect to 25% of the shares of common stock on July 1, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.
F4 The option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.